[ET Net News Agency, 7 December 2018] Nomura lowered its target price for New China
Life (NCI)(01336) to HK$57.5 from HK$61.9 and maintained its "buy" rating.
The research house believes that NCI will continue to stick to business transformation
strategy. The continuous business mix shift in 2018 demonstrated NCI management's
commitment to the business transformation strategy. FYP from health insurance accounted
for 56% of total FYP in 1H 2018, compared with 36% in 1H 2017.
Nomura expects NCI to deliver NBV growth of 12% YoY in FY2019 driven by FYP growth of
5.2% YoY and margin improvement. It cut its FY2018-19 EV forecast by 4%. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01336 NCI
Nominal 
14.320 0.000 (0.000%) Others
07/12/2018 10:04
[I-bank focus]Nomura trims New China Life (01336) to HK$57.5
| Remark: | Real time quote last updated: 26/04/2024 09:28 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |